| Unique ID issued by UMIN | UMIN000056296 |
|---|---|
| Receipt number | R000063964 |
| Scientific Title | The Efficacy and Safety of Scalp Cooling Therapy for Patients with Gynecologic Malignancies: A Prospective Observational Study |
| Date of disclosure of the study information | 2025/01/01 |
| Last modified on | 2025/05/30 12:43:08 |
The Efficacy and Safety of Scalp Cooling Therapy for Patients with Gynecologic Malignancies: A Prospective Observational Study
The Efficacy and Safety of Scalp Cooling Therapy for Patients with Gynecologic Malignancies: A Prospective Observational Study
The Efficacy and Safety of Scalp Cooling Therapy for Patients with Gynecologic Malignancies: A Prospective Observational Study
The Efficacy and Safety of Scalp Cooling Therapy for Patients with Gynecologic Malignancies: A Prospective Observational Study
| Japan |
Gynecologic Malignancies
| Obstetrics and Gynecology |
Malignancy
NO
This study aims to clarify the safety and efficacy of scalp cooling therapy for preventing chemotherapy-induced hair loss in patients with gynecologic malignancies, with the goal of establishing and promoting scalp cooling therapy in the field of gynecologic oncology.
Efficacy
The effect of hair loss prevention after six courses of TC or TCBEV therapy combined with scalp cooling therapy following radical surgery in patients with gynecologic malignancies.
Observational
| 20 | years-old | <= |
| 80 | years-old | > |
Female
If the following criteria are met, the attending physician will confirm eligibility on the case registration form and proceed with enrollment:
Diagnosis of a gynecologic malignancy cervical cancer, endometrial cancer, or ovarian cancer.
Radical surgery has been performed.
Six cycles of TC or TCBEV therapy are planned as postoperative adjuvant chemotherapy.
Aged 20 years or older and under 80 years.
Performance Status 0 - 2.
Major organ functions are preserved.
Patient is willing to undergo anticancer therapy combined with scalp cooling therapy.
Written informed consent for participation in the study has been obtained from the patient.
(1) Skin diseases on the scalp
(2) Alopecia (especially male-generated alopecia)
(3) History of treatment with head radiation therapy
(4)Allergy to Paclitaxel or Carboplatin
(5) Allergy to silicone
(6) Pregnant, lactating, may be pregnant, or intend to become pregnant
(7) Ischemic heart disease (angina pectoris or myocardial infarction), concomitant cardiomyopathy, or history of cardiomyopathy
(8) Has an active infection
(9) Interstitial pneumonia or pulmonary fibrosis
(10) Poorly controlled diabetes mellitus (HbA1c(NGSP) > 10.0%)
(11) Concurrent overlapping cancers
40
| 1st name | SHINYA |
| Middle name | |
| Last name | OKI |
Keio University School of Medicine
Department of Obstetrics and Gynecology
160-8582
35 Shinanomachi, Shinjuku-ku, Tokyo
03-3353-1211
ooki@keio.jp
| 1st name | SHINYA |
| Middle name | |
| Last name | OKI |
Keio University School of Medicine
Department of Obstetrics and Gynecology
160-8582
35 Shinanomachi, Shinjuku-ku, Tokyo
03-3353-1211
ooki@keio.jp
Keio University School of Medicine
none
Other
Keio University School of Medicine Ethics Committee
35 Shinanomachi, Shinjuku-ku, Tokyo
03-3353-1211
med-rinri-ft_pt@adst.keio.ac.jp
NO
| 2025 | Year | 01 | Month | 01 | Day |
Unpublished
Open public recruiting
| 2024 | Year | 11 | Month | 25 | Day |
| 2025 | Year | 02 | Month | 12 | Day |
| 2025 | Year | 01 | Month | 01 | Day |
| 2028 | Year | 12 | Month | 31 | Day |
no specific data
| 2024 | Year | 11 | Month | 28 | Day |
| 2025 | Year | 05 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000063964